Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.
Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Jang H, et al. Among authors: sypsa v. Clin Gastroenterol Hepatol. 2022 Jun;20(6):1343-1353.e16. doi: 10.1016/j.cgh.2021.09.001. Epub 2021 Sep 6. Clin Gastroenterol Hepatol. 2022. PMID: 34500103
Significance of IgM anti-HCV core level in chronic hepatitis C.
Papatheodoridis GV, Delladetsima JK, Katsoulidou A, Sypsa V, Albrecht M, Michel G, Hatzakis A, Tassopoulos NC. Papatheodoridis GV, et al. Among authors: sypsa v. J Hepatol. 1997 Jul;27(1):36-41. doi: 10.1016/s0168-8278(97)80277-2. J Hepatol. 1997. PMID: 9252071
A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.
Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vafiadis I, Avgerinos A, Tzathas C, Manolakopoulos S, Ketikoglou I, Aggelis P, Goritsas K, Giannoulis G, Hatzis G G, Thomopoulos K, Akriviadis E, Sypsa V, Hatzakis A. Tassopoulos NC, et al. Among authors: sypsa v. J Viral Hepat. 2003 May;10(3):189-96. doi: 10.1046/j.1365-2893.2003.00406.x. J Viral Hepat. 2003. PMID: 12753337 Clinical Trial.
Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.
Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G, Sypsa V, Hatzakis A. Ntziora F, et al. Among authors: sypsa v. J Clin Microbiol. 2009 Aug;47(8):2544-50. doi: 10.1128/JCM.00045-09. Epub 2009 Jun 24. J Clin Microbiol. 2009. PMID: 19553583 Free PMC article.
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis GV, et al. Among authors: sypsa v. J Hepatol. 2015 Feb;62(2):363-70. doi: 10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6. J Hepatol. 2015. PMID: 25195548
167 results